2024-07-30 15:16:09 ET
Nautilus Biotechnology, Inc. (NAUT)
Q2 2024 Earnings Conference Call
July 30, 2024 08:30 ET
Company Participants
Ji-Yon Yi - Investor Relations
Sujal Patel - Co-Founder & Chief Executive Officer
Parag Mallick - Co-Founder & Chief Scientist
Anna Mowry - Chief Financial Officer
Conference Call Participants
Matt Sykes - Goldman Sachs
Tycho Peterson - Jefferies
Dan Brennan - TD Cowen
Presentation
Operator
Good day and thank you for standing by and welcome to Nautilus Q2 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today to Ji-Yon Yi, Investor Relations. Please go ahead.
Ji-Yon Yi
Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30, 2024. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to Investor Relations at nautilus.bio. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, July 30, 2024....
Read the full article on Seeking Alpha
For further details see:
Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript